News | August 02, 2022
Cadila launches generic sitagliptin versions to treat uncontrolled type 2 diabetes
The two generic drugs have been launched under the brand names Jankey & Sitenali.
The two generic drugs have been launched under the brand names Jankey & Sitenali.
These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens
The innovative Fixed-Dose Combination will help improving the glycemic control among adult patients with insulin resistance, those whose diabetes is uncontrolled by metformin; and also those who require addition of Teneliglitptin and Pioglitazone as separate drugs.
In a European work-sharing procedure (WSP), Glucophage was approved as the first oral anti-diabetic medication to be used safely from conception to birth
Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy
Key takeaways of Q3FY22 quarter & conference call highlights
The start-up has announced the scheme to mark World Diabetes Day
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
A total of 12 generic medicines have been included in the list
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
Subscribe To Our Newsletter & Stay Updated
